Faster Answers, Better Decisions: ADLM 2026 Highlights

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.

PRNewsWire • Aug 27, 2026

QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?

QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.

Zacks Investment Research • Aug 17, 2026

Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?

QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.

Zacks Investment Research • Aug 17, 2026

QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns

QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.

Zacks Investment Research • Aug 17, 2026

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered

QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.

Zacks Investment Research • Aug 10, 2026

QuidelOrtho Q2 Earnings Call Highlights

QuidelOrtho NASDAQ: QDEL reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance.

MarketBeat • Aug 7, 2026

QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript

QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 7, 2026

QuidelOrtho Reports Second Quarter 2026 Financial Results

― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ―  ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company updates full-year 2026 financial guidance ― SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026. Key Second Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $631 million, an increase of 3% as reported and 2% in constant currency.

PRNewsWire • Aug 6, 2026

QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates

QuidelOrtho (QDEL) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.12 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Implied Volatility Surging for QuidelOrtho Stock Options

Investors need to pay close attention to QDEL stock based on the movements in the options market lately.

Zacks Investment Research • Aug 5, 2026